ClinicalTrials.gg
Active, not recruitingNCT06675864Updated Sep 4, 2026

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

A Phase 1/2 interventional study of rapcabtagene autoleucel (YTB323) in Progressive Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 18 sites in 7 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis — 1 open to participants now, 2 under way, 1 of them phase 3. Multiple Sclerosis, Chronic Progressive · Novartis.

Started
2024
with 1 other
Phase 1/2
Only one
of the 16
Registered
13th of 16
by date

Among the 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis, this one is one of 2 that started in 2024, is the only one in phase 1/2, and was the 13th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

1 of the 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis, or all of them as a file.
02

Study summary

This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

Read the detailed description

All participants in this study will receive YTB323. Both the participant and the study doctor will know the participant is getting YTB323. Participants will be given one dose of YTB323. Different groups of participants may receive a higher dose of YTB323, if proven to be safe for every participant at the lower dose. Participants are in this study for 2 years and will be followed for an additional 13 years in a long-term follow up study. The main question this trial is designed to answer: Is YTB323 treatment safe for participants with progressive MS?

03

Conditions studied

  • Progressive Multiple Sclerosis

Keywords

  • Chimeric Antigen Receptor T cells
  • CAR-T
  • YTB323
  • Multiple Sclerosis
  • MS
  • Progressive Multiple Sclerosis
  • PMS
  • rapcabtagene autoleucel
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female participants 18 to 60 years (inclusive) at screening.
  2. Signed must be obtained prior to participation in the study.
  3. Able to communicate well with the investigator, to understand and comply with the requirements of the study including:

    • Able to undergo lumbar puncture (LP), blood draws, tolerate brain and spinal MRI, and able to participate and tolerate all study procedures at study visits.
  4. Diagnosis of SPMS or PPMS according to the 2017 McDonald diagnostic criteria (Thompson et al 2018) as confirmed at screening visit.
  5. Less than 15 years (inclusive) from onset of first MS symptoms as determined by the investigator during screening.
  6. Ambulatory Patients (EDSS 3 to 6.5 inclusive) at screening.
  7. Evidence of recent (within 24 months) disease progression of ≥1.00 on the EDSS scale.
  8. No relapse in the last 24 months at screening.
  9. No Gd-enhancing lesion on brain or spinal cord MRI at screening.
  10. Participants must receive or be current on all recommended vaccinations according to institutional, local, or global guidelines for patients at least 6 weeks prior to lymphodepletion.

Key Exclusion Criteria:

  1. Diagnosis of relapsing multiple sclerosis (RMS) or active PMS according to the 2017 revision of the McDonald diagnostic criteria (Thompson et al 2018) at screening.
  2. History of, or current, CNS disease except MS (e.g. stroke, traumatic brain or spinal injury, history or presence of myelopathy, history of seizures or epilepsy) or neurological disorders which may mimic MS at screening.
  3. Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 6 months prior to or during screening).
  4. Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or neurological symptoms consistent with PML prior to or during screening.
  5. Clinically significant, active, opportunistic, chronic or recurrent infection (including positive for or ) confirmed by clinical evidence, imaging, or positive laboratory tests one month prior to leukapheresis.
  6. Have donated blood or experienced a loss of blood > 400 mL within 3 months prior screening, or longer if required by local regulations.
  7. Any prior stem cell therapy or organ transplantation or gene therapy.
  8. Any to LP, including but not limited to:

    • Known or suspected structural abnormality of the lumbar spine that, in the opinion of the Investigator, may interfere with the performance of the LP, or increase the risk of the procedure for the participant.
    • Presence of risk for increased or uncontrolled bleeding (including but not limited to vascular abnormalities or neoplasms at or near the LP site, disorders of the coagulation cascade, function, or platelet count).
    • Participants on anticoagulants (e.g., warfarin) or antiplatelets [except for low-dose aspirin (100 mg/day or lower) and low-dose nonsteroidal anti-inflammatory drugs such as ibuprofen (600 mg/day or lower) which are allowed], are not eligible to participate.
  9. Not willing or able to have MRI scans as per protocol e.g. due to claustrophobia, or absolute contraindications to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator).
  10. Pregnant or nursing (lactating) women.
  11. Past surgical history of splenectomy.
  12. Evidence of active or latent tuberculosis (TB) infection by QuantiFERON® TB-Gold assay (or equivalent) performed at Screening by central lab. In case of unclear or indeterminate test results, the Investigator should consult with an infectious disease expert to exclude the diagnosis of active or latent TB infection and document this in the source data. Participant should be excluded if they have any signs of active TB observed in available lung imaging (e.g., X-ray or HRCT).
  13. Any psychiatric, pulmonary (including, history of or active severe respiratory disease, including , interstitial lung disease or pulmonary fibrosis), renal, hepatic, endocrine, metabolic (e.g. severe hypoproteinemia due to nephrotic syndrome), hematological disorders or gastrointestinal disease that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant, prior to or during screening.
  14. Grade 2 or higher thromboembolic event in the past 4 weeks prior to or during Screening or evidence of disorders of coagulation or platelet function including subjects that require chronic use of anticoagulation or antiplatelet drugs (please refer to the key exclusion criteria no. 8 for the exceptions).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    YTB323 Cohort 1

    Participants will receive one dose of YTB323

    Biological: rapcabtagene autoleucel (YTB323)

  • Experimental
    YTB323 Cohort 2

    Participants will receive one dose of YTB323

    Biological: rapcabtagene autoleucel (YTB323)

  • Experimental
    YTB323 Cohort 3

    Participants will receive one dose of YTB323

    Biological: rapcabtagene autoleucel (YTB323)

  • Experimental
    YTB323 Cohort 4

    Participants will receive one dose of YTB323

    Biological: rapcabtagene autoleucel (YTB323)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs)

    Occurrence, severity, and frequency of dose limiting toxicities (DLTs), AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs), laboratory parameters, neurological status and magnetic resonance (MRI) of the brain and spinal cord qualifying and reported as AEs.

    Time frame: Day 1 through Year 2

Secondary outcomes

  1. Measure of Disability: Expanded Disability Status Scale (EDSS).

    EDSS is used to measure the change in disability level in participants using a scale from 0 to 10. The higher the score, the greater the degree of disability.

    Time frame: Day 1 through Year 2

  2. Measure of Disability: Short Form Health Survey (SF-36 v2)

    The Short Form Health Survey (SF-36 v2) is a widely used and extensively studied instrument to measure health-related quality of life among healthy participants and participants with acute and chronic conditions. It consists of eight subscales that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The SF 36 has proven useful in monitoring general and specific populations, comparing the relative burden of different diseases, differentiating the health benefits produced by different treatments, and in screening individual participants.

    Time frame: Day 1 through Year 2

  3. Measure of Disability: Timed 25 Foot Walk (T25FW)

    The T25FW is a mobility test based on a timed walk of 25 feet that is administered by a trained administrator. The participant is directed to walk the clearly marked 25-foot distance as quickly as possible. Longer completion time corresponds with decreased mobility.

    Time frame: Day 1 through Year 2

  4. Measure of Disability: 9 Hole Peg Test (9HPT)

    The 9HPT is a finger dexterity test that is administered by a trained administrator. The participant is directed to put 9 pegs, one by one, onto and then off the holder board as quickly as possible starting with using only the dominant hand, and then repeated with the non-dominant hand. Longer completion times are associated with decreased finger dexterity.

    Time frame: Day 1 through Year 2

  5. Measure of Disability: Symbol Digit Modalities Test (SDMT)

    The SDMT is a timed cognition test administered by a trained administrator. The test assesses sustained attention, processing speed, visual scanning, and motor speed to determine cognitive impairment. Participants are given a coding key which contains abstract symbols that correspond to specific numbers. Participants are timed how quickly and accurately they are able to substitute the symbols for the numbers and is scored by the number of correctly coded items.

    Time frame: Day 1 through Year 2

  6. Modified Fatigue Impact Scale (MFIS)

    The MFIS is a questionnaire to assess fatigue-related symptoms in patients with MS.

    Time frame: Day 1 through Year 2

  7. Whole Blood Pharmacokinetics (PK) of YTB323 - CMAX

    Measured by Cmax - The maximum plasma concentration of YTB323

    Time frame: Day 1 through Year 2

  8. Whole Blood Pharmacokinetics (PK) of YTB323 - AUC

    Measured by AUC - Area under the curve of YTB323

    Time frame: Day 1 Through Year 2

  9. Whole Blood Pharmacokinetics (PK) of YTB323 - Tmax

    Measured by Tmax - Time to Reach the Maximum Concentration After Drug Administration of YTB323

    Time frame: Day 1 Through Year 2

  10. Whole Blood Pharmacokinetics (PK) of YTB323 - Clast

    Clast is defined as the Last observed (quantifiable) plasma concentration (Clast

    Time frame: Day 1 Through Year 2

  11. Whole Blood Pharmacokinetics (PK) of YTB323 - Tlast

    Tlast is defined as Time of Last Measurable Concentration

    Time frame: Day 1 through Year 2

  12. Humoral Immunogenicity of YTB323

    Incidence and prevalence of pre-existing and treatment induced humoral immunogenicity of YTB323

    Time frame: Day 1 through Year 2

  13. Cellular Immunogenicity of YTB323

    Incidence and prevalence of pre-existing and treatment induced cellular immunogenicity of YTB323

    Time frame: Day 1 through Year 2

  14. Safety data including dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs) from each dose level

    Safety data from each dose level will be used to assess safe dose-level(s) to be continued in phase 2 and later clinical studies

    Time frame: Day 1 through Year 2

07

Study locations

18 sites
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Québec, Quebec G1J 1Z4, Canada
  • Novartis Investigative Site
    Bron, 69677, France
  • Novartis Investigative Site
    Montpellier, 34090, France
  • Novartis Investigative Site
    Nancy, 54035, France
  • Novartis Investigative Site
    Rennes, 35033, France
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Milan, MI 20132, Italy
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Madrid, 28222, Spain
  • Novartis Investigative Site
    Málaga, 29010, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jun 2030, 66 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 5, 2024
StartActual
Dec 12, 2024
Primary completionEst.
Jun 14, 2030
CompletionEst.
Jun 14, 2030
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06675864
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Dec 12, 2024
Primary completion
Jun 14, 2030 (estimated)
Completion
Jun 14, 2030 (estimated)
Last update
Sep 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rapcabtagene autoleucel

Start the discussion